Disis ML - Search Results

1

Insulin-like growth factor-binding protein-2 is a target for the immunomodulation of breast cancer.

Park KH, Gad E, Goodell V, Dang Y, Wild T, Higgins D, Fintak P, Childs J, Dela Rosa C, Disis ML. Park KH, et al. Among authors: disis ml. Cancer Res. 2008 Oct 15;68(20):8400-9. doi: 10.1158/0008-5472.CAN-07-5891. Cancer Res. 2008. PMID: 18922913 Free PMC article.

2

Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer.

Disis ML, Calenoff E, McLaughlin G, Murphy AE, Chen W, Groner B, Jeschke M, Lydon N, McGlynn E, Livingston RB, et al. Disis ML, et al. Cancer Res. 1994 Jan 1;54(1):16-20. Cancer Res. 1994. PMID: 7505195

3

HER-2/neu protein: a target for antigen-specific immunotherapy of human cancer.

Disis ML, Cheever MA. Disis ML, et al. Adv Cancer Res. 1997;71:343-71. doi: 10.1016/s0065-230x(08)60103-7. Adv Cancer Res. 1997. PMID: 9111870 Review.

4

Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine.

Disis ML, Grabstein KH, Sleath PR, Cheever MA. Disis ML, et al. Clin Cancer Res. 1999 Jun;5(6):1289-97. Clin Cancer Res. 1999. PMID: 10389911 Clinical Trial.

5

Pre-existent immunity to the HER-2/neu oncogenic protein in patients with HER-2/neu overexpressing breast and ovarian cancer.

Disis ML, Knutson KL, Schiffman K, Rinn K, McNeel DG. Disis ML, et al. Breast Cancer Res Treat. 2000 Aug;62(3):245-52. doi: 10.1023/a:1006438507898. Breast Cancer Res Treat. 2000. PMID: 11072789

6

Identification of T helper epitopes from prostatic acid phosphatase.

McNeel DG, Nguyen LD, Disis ML. McNeel DG, et al. Among authors: disis ml. Cancer Res. 2001 Jul 1;61(13):5161-7. Cancer Res. 2001. PMID: 11431355

7

Vaccination against the HER-2/neu oncogenic protein.

Bernhard H, Salazar L, Schiffman K, Smorlesi A, Schmidt B, Knutson KL, Disis ML. Bernhard H, et al. Among authors: disis ml. Endocr Relat Cancer. 2002 Mar;9(1):33-44. doi: 10.1677/erc.0.0090033. Endocr Relat Cancer. 2002. PMID: 11914181 Review.

8

Flt3 ligand as a vaccine adjuvant in association with HER-2/neu peptide-based vaccines in patients with HER-2/neu-overexpressing cancers.

Disis ML, Rinn K, Knutson KL, Davis D, Caron D, dela Rosa C, Schiffman K. Disis ML, et al. Blood. 2002 Apr 15;99(8):2845-50. doi: 10.1182/blood.v99.8.2845. Blood. 2002. PMID: 11929774 Free article. Clinical Trial.

9

Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity.

Knutson KL, Schiffman K, Cheever MA, Disis ML. Knutson KL, et al. Among authors: disis ml. Clin Cancer Res. 2002 May;8(5):1014-8. Clin Cancer Res. 2002. PMID: 12006513 Clinical Trial.

10

Identification of tumor-specific antibodies in patients with breast cancer vaccinated with gene-modified allogeneic tumor cells.

Dols A, Meijer SL, Hu HM, Goodell V, Disis ML, Von Mensdorff-Pouilly S, Verheijen R, Alvord WG, Smith JW 2nd, Urba WJ, Fox BA. Dols A, et al. Among authors: disis ml. J Immunother. 2003 Mar-Apr;26(2):163-70. doi: 10.1097/00002371-200303000-00009. J Immunother. 2003. PMID: 12616108 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

305 results

Search Page

Filters